The following video is part of our "Motley Fool Conversations" series, in which analyst John Reeves and advisor David Meier discuss topics across the investing world.
Johnson & Johnson has always been a favorite of investors. It's a diversified company that has always paid out a solid dividend. The company has struggled of late, however. David thinks the company is on the verge of a rally. The acquisition of device-maker Synthes gives it a strong position against its competitors, and it has a couple of promising drugs in its pipeline. Turnarounds are not always easy, but Johnson & Johnson's attractive price and dividend yield might just make up for the risk.
Johnson & Johnson offers a very attractive dividend yield, though it still has work to do to get back to it's former glory. If you'd like to learn about some additional outstanding dividend payers, The Motley Fool has compiled a special free report outlining our top nine dependable, dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here to discover the winners we've picked.
David Meier has no positions in the stocks mentioned above. John Reeves has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. Motley Fool newsletter services recommend Johnson & Johnson and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.